Mandate

Vinge has advised Fortum in connection with the divestment of its recycling and waste business

Vinge, alongside among others Castrén & Snellman, has advised Fortum in connection with the divestment of its recycling and waste business to Summa Equity through its portfolio company NG Group. The debt free purchase price is approximately EUR 800 million.

The recycling and waste business subject to the divestment comprises municipal and industrial waste management and recycling services for handling and recycling of plastics, metals, ash, slag and hazardous waste.  The businesses are located in Finland, Sweden, Denmark and Norway and currently employ approximately 900 employees. 

Vinge’s team mainly consisted of Peter Sundgren and Gustav Wahlberg (M&A), Johan Cederblad and Lina Österberg (Environmental), Martin Boström and Elis Allmark (Corporate Commercial), Sam Seddigh and Agnes Pigg (Employment), Linn Adelwald and Karl-Gustaw Tobola (Banking & Finance), Frida Ställborn (Real Estate) and Daniel Wendelsson, David Olander, Dagne Sabockis and Lovisa Lewin (Regulatory)

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026